Pharmacy benefit management company, or PBM, Express Scripts (NASDAQ: ESRX )
has done quite well for investors in the past, but Wall Street is less
confident about the future. Analysts are skeptical that, with the large
advances already made in the shift to generics, Express Scripts can
leverage formulary design, producer discounts, mail delivery and other
drivers to continue generating double-digit free cash flow growth.
That skepticism could work in investors' favor, though, as Express
Scripts looks like one of the relatively few meaningfully undervalued
large health care companies.
Read more here:
Can Express Scripts Holding Co. Beat Expectations Again?
No comments:
Post a Comment